Abstract Circulating tumour DNA (ctDNA) detection and monitoring has enormous potential clinical utility in oncology. We describe here a fast, flexible and cost-effective method to profile multiple genes simultaneously in low input cell-free DNA (cfDNA): Next Generation-Targeted Amplicon Sequencing (NG-TAS). We designed a panel of 377 amplicons spanning 20 cancer genes and tested the NG-TAS pipeline using cell-free DNA from two hapmap lymphoblastoid cell lines. NG-TAS consistently detected mutations in cfDNA when mutation allele fraction was >1%. We applied NG-TAS to a clinical cohort of metastatic breast cancer patients, demonstrating its potential in monitoring the disease. The computational pipeline is available at: https://github.com/cc...
Targeted deep sequencing across broad genomic regions has been used to detect circulating tumor DNA ...
We prospectively performed a longitudinal analysis of circulating tumor DNA (ctDNA) from 149 plasma ...
Detection of clinically actionable mutations in diagnostic tumour specimens aids in the selection of...
Abstract Circulating tumour DNA (ctDNA) detection and monitoring have enormous potential clinical ut...
Circulating tumour DNA (ctDNA) detection and monitoring have enormous potential clinical utility in ...
Recent advances in next generation sequencing (NGS) have allowed significant improvement in the sens...
Cancer is a disease of complex genetic alterations, and comprehensive genetic diagnosis is beneficia...
Background: Breast cancer tissues are heterogeneous and show diverse somatic mutations and somatic c...
textabstractThe use of blood-circulating cell-free DNA (cfDNA) as 'liquid-biopsy' is explored worldw...
ObjectiveClinical diagnostic sequencing of circulating tumour DNA (ctDNA) is well advanced for adult...
Circulating tumour DNA (ctDNA) can be used to profile, detect, and monitor cancers. Technical advanc...
Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typi...
Breast cancer (BC) is the most prevalent cancer in women. While usually detected when localized, inv...
<div><p>Next-generation sequencing of cell-free circulating solid tumor DNA addresses two challenges...
The circulating free tumor DNA (ctDNA) represents an alternative, minimally invasive source of tumor...
Targeted deep sequencing across broad genomic regions has been used to detect circulating tumor DNA ...
We prospectively performed a longitudinal analysis of circulating tumor DNA (ctDNA) from 149 plasma ...
Detection of clinically actionable mutations in diagnostic tumour specimens aids in the selection of...
Abstract Circulating tumour DNA (ctDNA) detection and monitoring have enormous potential clinical ut...
Circulating tumour DNA (ctDNA) detection and monitoring have enormous potential clinical utility in ...
Recent advances in next generation sequencing (NGS) have allowed significant improvement in the sens...
Cancer is a disease of complex genetic alterations, and comprehensive genetic diagnosis is beneficia...
Background: Breast cancer tissues are heterogeneous and show diverse somatic mutations and somatic c...
textabstractThe use of blood-circulating cell-free DNA (cfDNA) as 'liquid-biopsy' is explored worldw...
ObjectiveClinical diagnostic sequencing of circulating tumour DNA (ctDNA) is well advanced for adult...
Circulating tumour DNA (ctDNA) can be used to profile, detect, and monitor cancers. Technical advanc...
Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typi...
Breast cancer (BC) is the most prevalent cancer in women. While usually detected when localized, inv...
<div><p>Next-generation sequencing of cell-free circulating solid tumor DNA addresses two challenges...
The circulating free tumor DNA (ctDNA) represents an alternative, minimally invasive source of tumor...
Targeted deep sequencing across broad genomic regions has been used to detect circulating tumor DNA ...
We prospectively performed a longitudinal analysis of circulating tumor DNA (ctDNA) from 149 plasma ...
Detection of clinically actionable mutations in diagnostic tumour specimens aids in the selection of...